Business Wire

Startups to Display Breakthroughs in Smart Cities and IoT at CES Unveiled Amsterdam

Del

The Consumer Technology Association (CTA) today announced that more than 450 tech executives are slated to attend the first CES Unveiled Amsterdam, tracking to become CTA’s most attended inaugural CES Unveiled event abroad. A part of the CES Unveiled series, which provide media, tech companies and key industry influencers the opportunity to gather in cities around the world and showcase their latest innovations, CES Unveiled Amsterdam will serve as a preview for the cutting-edge technology to be displayed at CES® 2018. CES Unveiled Amsterdam will be held on Thursday, October 26, 2017 at the Beurs van Berlage.

“The level of excitement CES Unveiled Amsterdam has received from the region is unprecedented,” said Gary Shapiro, president and CEO, Consumer Technology Association. “The Netherlands is the European leader in smart cities initiatives, and the country’s commitment to tech innovation has transpired through the increase in Dutch startup numbers at CES, which increased dramatically from three in 2016 to 24 in 2017. I look forward to seeing what breakthroughs will be on display at this inaugural event.”

Budding startups from throughout the region will highlight their latest breakthroughs in Smart Cities, a newly dedicated Marketplace at CES 2018 and the internet of things (IoT). Attendees, including top tier media, key influencers, buyers and industry affiliates, will have the opportunity to interact with disruptive tech across numerous product categories, including Augmented and Virtual Reality, Wearables, Robotics and more.

StartupDelta, led by Prince Constantijn of the Netherlands, is partnering with CES Unveiled Amsterdam to bring the region’s most innovative startups to the event. StartupDelta plans to continue to grow the number of startups from the country participating in Eureka Park, the flagship startup destination at CES, in January.

CES Innovation Honorees from the Netherlands and surrounding regions, including Belgium, Denmark, Germany, Sweden and UK, will be announced at CES Unveiled Amsterdam and their products displayed during the event’s Networking Reception & Tabletop Exhibition. The CES Innovation Awards is an annual competition celebrating outstanding design and engineering in consumer technology products and selects recipients across 28 product categories with Honorees being featured at CES 2018, January 9-12, 2018 in Las Vegas, NV.

A full exhibitor lineup and programming schedule will be released in the coming weeks. For more information about exhibiting or attending the event, please visit CES.tech/UnveiledAmsterdam. To learn more about the CES Unveiled series, including the annual CES Unveiled Paris to be held on October 24, 2017 at the Palais Brongniart, visit CES.tech/CESUnveiled.

High-definition video b-roll from CES is available for easy download on CESbroll.com

About CES:

CES® is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM, it attracts the world's business leaders and pioneering thinkers. Check out CES video highlights. Follow CES online at CES.tech and on social.

About Consumer Technology Association:

Consumer Technology Association (CTA)™ is the trade association representing the $321 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.

UPCOMING EVENTS

  • Innovate Celebrate - Register
    October 9-11, San Francisco, CA
  • CES Unveiled Paris - Register
    October 24, Paris, France
  • CES Unveiled Amsterdam - Register
    October 26, Amsterdam, Netherlands
  • CT Hall of Fame Dinner
    November 7, New York, NY
  • CES Unveiled New York
    November 9, New York, NY
  • CES Unveiled Las Vegas
    January 7, Las Vegas, NV
  • CES 2018 - Register
    January 9-12, Las Vegas, NV
  • CES Asia 2018
    June 13-15, Shanghai, China

Contact information

Consumer Technology Association (CTA)
Teresa Hsu, 703-907-5259
thsu@cta.tech
www.CTA.tech
or
Bernice Morquette, 703-907-7651
bmorquette@cta.tech
www.CTA.tech

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31Pressemelding

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20Pressemelding

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31Pressemelding

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom